Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 3/20 | 0.55 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.43 |
| ▸ | AKT1 | P31749 | 1/20 | 0.42 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.42 |
| ▸ | SOS1 | Q07889 | 3/20 | 0.41 |
| ▸ | MAOB | P27338 | 8/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
| ▸ | TAAR5 | O14804 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12238998 | 0.85 | ROCK2 (0.51) | ROCK2ROCK1HTR2ASLC6A4ST14 | |
| SCHEMBL29918426 | 0.83 | TTR (0.46) | ROCK2ROCK1HTR2ASLC6A4SOS1 | |
| SCHEMBL9900607 | 0.83 | TTR (0.46) | ROCK2ROCK1HTR2ASLC6A4SOS1 | |
| SCHEMBL13904122 | 0.83 | ROCK2 (0.55) | ROCK2ROCK1ST14AKT1RPS6KA1 | |
| SCHEMBL12239000 | 0.83 | ROCK2 (0.52) | ROCK2ROCK1HTR2ASLC6A4SOS1 | |
| SCHEMBL4369759 | 0.82 | ST14 (0.64) | ST14SOS1MAOBAOC3 | |
| SCHEMBL758255 | 0.82 | ROCK2 (0.51) | ROCK2ROCK1ST14AKT1RPS6KA1 | |
| SCHEMBL921313 | 0.81 | ROCK2 (0.50) | ROCK2ROCK1HTR2ASLC6A4ST14 | |
| SCHEMBL9904465 | 0.81 | ROCK2 (0.41) | ROCK2ROCK1HTR2ASLC6A4SOS1 | |
| SCHEMBL110823 | 0.80 | LOXL2 (0.52) | ST14TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8975400-B2 | 2,3-dihydroimidazo[1, 2-c] pyrimidin-5(1 H)-one compounds use as LP-PLA2 inhibitors | GLAXO GROUP LIMITED (GB) | 2015-03-10 | — | — | US | disclosed |
| US-8975400-B2 | 2,3-dihydroimidazo[1, 2-c] pyrimidin-5(1 H)-one compounds use as LP-PLA2 inhibitors | GLAXO GROUP LIMITED (GB) | 2015-03-10 | — | — | US | disclosed |
| US-8975400-B2 | 2,3-dihydroimidazo[1, 2-c] pyrimidin-5(1 H)-one compounds use as LP-PLA2 inhibitors | GLAXO GROUP LIMITED (GB) | 2015-03-10 | — | — | US | disclosed |
| US-20140179715-A1 | 2,3-DIHYDROIMIDAZO[1 ,2-c] PYRIMIDIN-5(1 H)-ONE COMPOUNDS USE AS LP-PLA2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2014-06-26 | — | — | US | disclosed |
| US-20140179715-A1 | 2,3-DIHYDROIMIDAZO[1 ,2-c] PYRIMIDIN-5(1 H)-ONE COMPOUNDS USE AS LP-PLA2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2014-06-26 | — | — | US | disclosed |
| US-20140179715-A1 | 2,3-DIHYDROIMIDAZO[1 ,2-c] PYRIMIDIN-5(1 H)-ONE COMPOUNDS USE AS LP-PLA2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2014-06-26 | — | — | US | disclosed |
| EP-2739627-A1 | 2,3-DIHYDROIMIDAZO[1,2-C]PYRIMIDIN-5(1H)-ONE COMPOUNDS USE AS LP-PLA² INHIBITORS | Glaxo Group Limited (GB) | 2014-06-11 | — | — | EP | disclosed |
| WO-2013013503-A1 | 2,3-DIHYDROIMIDAZO[1,2-C] PYRIMIDIN-5(1H)-ONE COMPOUNDS USE AS LP-PLA2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179715-A1 | 2,3-DIHYDROIMIDAZO[1 ,2-c] PYRIMIDIN-5(1 H)-ONE COMPOUNDS USE AS LP-PLA2 INHIBITORS | PLA2G4A, PLA2G4C, PLA2G4B | ROCK2 2490/4885ROCK1 2397/4885HTR2A 854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.